Which has stronger earnings and valuation, ARGX or ASND?

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.73 $1.29B $26.04 33.21 Ascendis Pharma A/S $814.57M 19.50 -$258M $8.67 29.36

Does the media refer more to ARGX or ASND?

In the previous week, argenex had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for argenex and 6 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.71 indicating that argenex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or ASND?

In the previous week, Revolution Medicines had 18 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Revolution Medicines and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Revolution Medicines' score of 0.36 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 10 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NTRA or ASND?

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Natera $2.31B 19.55 -$208.16M -$1.36 N/A Ascendis Pharma A/S $814.57M 19.50 -$258M $8.67 29.36

Does the media refer more to NTRA or ASND?

In the previous week, Natera had 33 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 39 mentions for Natera and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Natera's score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 16 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, ASND or BIIB?

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 19.50 -$258M $8.67 29.36 Biogen $9.89B 3.05 $1.29B $5.65 36.09

Does the media refer more to ASND or BIIB?

In the previous week, Biogen had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for Biogen and 6 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.71 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ASND or ALNY?

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Alnylam Pharmaceuticals' score of 0.10 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Ascendis Pharma A/S (ASND) Competitors

$254.57 -1.05 (-0.41%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$254.98 +0.41 (+0.16%)

As of 08:33 AM Eastern

Compare

ASND vs. ARGX, RVMD, NTRA, BIIB, and ALNY

Should you buy Ascendis Pharma A/S stock or one of its competitors? Ascendis Pharma A/S's main competitors and comparable companies include argenex (ARGX), Revolution Medicines (RVMD), Natera (NTRA), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascendis Pharma A/S compare to argenex?

argenex (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

Ascendis Pharma A/S has a net margin of 57.87% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

60.3% of argenex shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, argenex had 3 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 9 mentions for argenex and 6 mentions for Ascendis Pharma A/S. argenex's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.71 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.73	$1.29B	$26.04	33.21
Ascendis Pharma A/S	$814.57M	19.50	-$258M	$8.67	29.36

argenex presently has a consensus price target of $1,056.89, indicating a potential upside of 22.22%. Ascendis Pharma A/S has a consensus price target of $296.12, indicating a potential upside of 16.32%. Given argenex's higher probable upside, analysts plainly believe argenex is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06

Summary

argenex beats Ascendis Pharma A/S on 12 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

94.3% of Revolution Medicines shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has a net margin of 57.87% compared to Revolution Medicines' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Revolution Medicines presently has a consensus target price of $161.79, suggesting a potential downside of 21.29%. Ascendis Pharma A/S has a consensus target price of $296.12, suggesting a potential upside of 16.32%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06

Ascendis Pharma A/S has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$8.82	N/A
Ascendis Pharma A/S	$814.57M	19.50	-$258M	$8.67	29.36

In the previous week, Revolution Medicines had 18 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Revolution Medicines and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Revolution Medicines' score of 0.36 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	10 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ascendis Pharma A/S beats Revolution Medicines on 12 of the 16 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Natera?

Natera (NASDAQ:NTRA) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

In the previous week, Natera had 33 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 39 mentions for Natera and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Natera's score of 0.62 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	16 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Natera has higher revenue and earnings than Ascendis Pharma A/S. Natera is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	19.55	-$208.16M	-$1.36	N/A
Ascendis Pharma A/S	$814.57M	19.50	-$258M	$8.67	29.36

Natera presently has a consensus target price of $305.40, suggesting a potential downside of 2.34%. Ascendis Pharma A/S has a consensus target price of $296.12, suggesting a potential upside of 16.32%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	2 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.77
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06

Natera has a beta of 1.51, indicating that its stock price is 51% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Natera's net margin of -7.11%. Ascendis Pharma A/S's return on equity of 0.00% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.82%	-8.19%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

99.9% of Natera shares are held by institutional investors. 5.1% of Natera shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Natera on 8 of the 15 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Biogen?

Ascendis Pharma A/S (NASDAQ:ASND) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $296.12, suggesting a potential upside of 16.32%. Biogen has a consensus price target of $224.61, suggesting a potential upside of 10.16%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Ascendis Pharma A/S has a net margin of 57.87% compared to Biogen's net margin of 8.32%. Biogen's return on equity of 11.18% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Biogen	8.32%	11.18%	6.88%

87.9% of Biogen shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.3% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Biogen had 10 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 16 mentions for Biogen and 6 mentions for Ascendis Pharma A/S. Biogen's average media sentiment score of 0.77 beat Ascendis Pharma A/S's score of 0.71 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.50	-$258M	$8.67	29.36
Biogen	$9.89B	3.05	$1.29B	$5.65	36.09

Summary

Biogen beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Alnylam Pharmaceuticals had 12 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 18 mentions for Alnylam Pharmaceuticals and 6 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Alnylam Pharmaceuticals' score of 0.10 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.50	-$258M	$8.67	29.36
Alnylam Pharmaceuticals	$3.71B	7.97	$313.75M	$5.38	41.12

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Ascendis Pharma A/S currently has a consensus price target of $296.12, suggesting a potential upside of 16.32%. Alnylam Pharmaceuticals has a consensus price target of $396.72, suggesting a potential upside of 79.35%. Given Alnylam Pharmaceuticals' higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.06
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Ascendis Pharma A/S has a net margin of 57.87% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Summary

Alnylam Pharmaceuticals beats Ascendis Pharma A/S on 10 of the 17 factors compared between the two stocks.

Get Ascendis Pharma A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASND vs. The Competition

Export

Metric	Ascendis Pharma A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.94B	$3.71B	$7.08B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.34%
P/E Ratio	29.36	10.37	268.39	25.05
Price / Sales	19.50	1,227.72	573.03	74.61
Price / Cash	N/A	102.54	72.26	50.42
Price / Book	-85.71	17.81	13.16	6.18
Net Income	-$258M	-$13.23M	$3.44B	$347.05M
7 Day Performance	4.25%	3.23%	2.09%	1.24%
1 Month Performance	-5.87%	-1.13%	-0.25%	-0.65%
1 Year Performance	29.90%	59.42%	70.32%	20.12%

Ascendis Pharma A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASND Ascendis Pharma A/S	4.3415 of 5 stars	$254.57 -0.4%	$296.12 +16.3%	+29.9%	$15.94B	$814.57M	29.36	1,189	Upcoming Earnings
ARGX argenex	4.6695 of 5 stars	$830.79 -2.7%	$1,056.89 +27.2%	+35.3%	$53.42B	$4.25B	31.90	1,863
RVMD Revolution Medicines	2.1065 of 5 stars	$182.45 -2.7%	$144.67 -20.7%	+492.4%	$39.87B	$11.58M	N/A	250	Earnings Report Analyst Forecast
NTRA Natera	2.4636 of 5 stars	$270.36 +1.0%	$267.83 -0.9%	+99.1%	$38.35B	$2.50B	N/A	6,140	Earnings Report Analyst Forecast
BIIB Biogen	4.0649 of 5 stars	$201.82 -0.6%	$223.89 +10.9%	+59.3%	$29.99B	$9.89B	35.72	7,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASND) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Competitors

ASND vs. ARGX, RVMD, NTRA, BIIB, and ALNY

How does Ascendis Pharma A/S compare to argenex?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Summary

How does Ascendis Pharma A/S compare to Natera?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Competitors

ASND vs. ARGX, RVMD, NTRA, BIIB, and ALNY

How does Ascendis Pharma A/S compare to argenex?

Is ARGX or ASND more profitable?

Which has more volatility and risk, ARGX or ASND?

Do insiders and institutionals have more ownership in ARGX or ASND?

Does the media refer more to ARGX or ASND?

Which has stronger earnings and valuation, ARGX or ASND?

Do analysts rate ARGX or ASND?

Summary

How does Ascendis Pharma A/S compare to Revolution Medicines?

Do insiders & institutionals hold more shares of RVMD or ASND?

Is RVMD or ASND more profitable?

Which has more volatility & risk, RVMD or ASND?

Do analysts rate RVMD or ASND?

Which has stronger valuation & earnings, RVMD or ASND?

Does the media prefer RVMD or ASND?

Summary

How does Ascendis Pharma A/S compare to Natera?

Does the media refer more to NTRA or ASND?

Which has preferable earnings and valuation, NTRA or ASND?

Do analysts prefer NTRA or ASND?

Which has more risk and volatility, NTRA or ASND?

Is NTRA or ASND more profitable?

Do institutionals & insiders hold more shares of NTRA or ASND?

Summary

How does Ascendis Pharma A/S compare to Biogen?

Which has more volatility & risk, ASND or BIIB?

Do analysts prefer ASND or BIIB?

Is ASND or BIIB more profitable?

Do insiders and institutionals hold more shares of ASND or BIIB?

Does the media refer more to ASND or BIIB?

Which has better earnings & valuation, ASND or BIIB?

Summary

How does Ascendis Pharma A/S compare to Alnylam Pharmaceuticals?

Does the media refer more to ASND or ALNY?

Do insiders and institutionals hold more shares of ASND or ALNY?

Which has better earnings & valuation, ASND or ALNY?

Which has more volatility & risk, ASND or ALNY?

Do analysts prefer ASND or ALNY?

Is ASND or ALNY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASND vs. The Competition

Ascendis Pharma A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools